Fenofibrate with Statin: Safety and Recommendations

Safety of Fenofibrate-Statin Combination

The American College of Cardiology recommends that when statin-fibrate combination therapy is indicated, fenofibrate or fenofibric acid is preferred over gemfibrozil because of a reduced incidence of drug-drug interactions and lower risk of myopathy 1, 2
Fenofibrate-statin combination therapy is generally safe when used appropriately, with reports of rhabdomyolysis approximately 15 times lower for fenofibrate than for gemfibrozil when prescribed with statins (0.58 vs 8.6 cases per 1 million prescriptions) 2, 3
In the FIELD study, none of the approximately 1,000 patients on statin-fenofibrate combination therapy experienced rhabdomyolysis 2
The ACCORD study showed no statistically significant differences in the incidence of myositis, rhabdomyolysis, or elevations of hepatic transaminases with simvastatin-fenofibrate combination therapy compared to simvastatin monotherapy in patients with type 2 diabetes 2

Fenofibrate can be safely combined with any statin when clinically indicated 2
Fluvastatin may be used in combination with either gemfibrozil, fenofibrate, or fenofibric acid 2, 3
Gemfibrozil should be avoided in combination with lovastatin, pravastatin, and simvastatin 1, 2
FDA-approved product labeling indicates that gemfibrozil is contraindicated with simvastatin 2

The American College of Cardiology recommends monitoring patients for muscle symptoms, which may include pain, tenderness, or weakness 4
Baseline liver function tests and creatine kinase (CK) levels should be checked 4
More frequent CK measurements are indicated for patients with moderate CK elevations 4
Patients with risk factors for myopathy require closer monitoring 4, 5

Advanced age (especially >80 years), with women at higher risk than men 4
Small body frame and frailty 4
Multisystem disease (e.g., chronic renal insufficiency, especially due to diabetes) 4
Multiple medications 4
Perioperative periods 4

The American Diabetes Association notes that statin plus fibrate combination therapy has not been shown to improve atherosclerotic cardiovascular disease outcomes and is generally not recommended 6, 7

The American College of Cardiology recommends starting with low doses of statin when combining with fenofibrate 4
Consider withholding statin therapy during periods of major surgery 4
Use caution in elderly patients, particularly older thin or frail women 4
Monitor carefully in patients with diabetes combined with chronic renal failure 4

The combination of statin and fibrate is associated with an increased risk for abnormal transaminase levels, with liver enzyme elevations significantly higher in combination therapy 6, 7
The risk of rhabdomyolysis is more common with higher doses of statins and in patients with renal insufficiency 6, 7
Combination therapy should be reserved for cases where the benefits from ASCVD risk reduction or triglyceride lowering outweigh the potential risks 2